A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
Trial
Phase 1
Unknown
April 28, 2024
Diaphragmatic Thickness and Pulmonary Function in Parkinson's Disease
Trial
N/A
Completed
April 25, 2024
Virtual Reality and Fear of Falling in Parkinson's Disease
Trial
N/A
Unknown
April 25, 2024
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Trial
Phase 3
Completed
April 24, 2024
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Trial
Phase 1
Completed
April 24, 2024
Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease
Trial
Phase 4
Completed
April 24, 2024
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
Trial
Phase 2
Completed
April 24, 2024
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Trial
Phase 3
Completed
April 24, 2024
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Trial
Phase 3
Completed
April 24, 2024
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
Trial
Phase 2
Completed
April 24, 2024
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Trial
Phase 3
Completed
April 24, 2024
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Trial
Phase 3
Completed
April 24, 2024
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
Trial
Phase 3
Completed
April 24, 2024
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Trial
Phase 2
Completed
April 24, 2024
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
Trial
Phase 2
Completed
April 24, 2024
Identification of a Biomarker Predictive of Evolution of Parkinson Disease
Trial
Phase 2
Unknown
April 24, 2024
Keep On Keep Up for Parkinson's
Trial
N/A
Unknown
April 23, 2024
The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients
Trial
Phase 2
Completed
April 22, 2024
Efficacy of Probiotics for Parkinson Disease (PD)
Trial
N/A
Withdrawn
April 22, 2024
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
Trial
Phase 2
Completed
April 22, 2024